Opioids, as a class, are generally considered neutral in terms of their effects on CBF and CMRO₂. Early studies using low-resolution detection techniques, such as transcranial Doppler (TCD), suggested that opioids had minimal impact on global CBF. However, more recent studies using high-resolution techniques, such as MRI and PET, have revealed that opioids can alter regional CBF.
Two indirect effects matter more than any direct one. In a spontaneously breathing patient, opioid-induced hypoventilation raises PaCO₂ and with it CBF and ICP, so the neutral label holds only with normocapnia. And a bolus large enough to drop MAP can produce a brief rise in ICP in a patient with poor intracranial compliance, because autoregulatory vasodilation increases cerebral blood volume; the effect is avoided by giving opioids in a way that keeps blood pressure steady.
Fentanyl, for example, has been shown to increase CBF in areas such as the prefrontal cortex and caudate nucleus, which are involved in pain processing. Similarly, morphine and hydromorphone exhibit comparable effects, while sufentanil and remifentanil display a biphasic response, with low doses increasing CBF and higher doses causing a decrease in both CBF and cerebral metabolic rate of oxygen consumption (CMRO₂).
Vasomotor Reactivity and Cerebral Perfusion under Opioid Use
Despite the changes in regional CBF, vasomotor reactivity (VMR), the cerebrovascular response to changes in carbon dioxide, and pressure autoregulation both remain intact during opioid use, including during remifentanil infusion. Opioids therefore do not impair the brain's own regulation of its flow, which is crucial in maintaining stable cerebral perfusion during anesthesia.
Neuroprotective Potential of Opioids and Naloxone
Opioids may have potential neuroprotective effects, particularly through opioid receptor subtype-specific agonists. Preclinical studies indicate that endogenous opioids might protect the brain after traumatic brain injury (TBI), though no opioid receptor-specific agonists have been thoroughly evaluated in clinical trials for conditions like ischemic stroke or TBI. Additionally, naloxone, an opioid receptor antagonist, has shown the ability to reduce CBF, though its exact mechanism is unclear. Some studies suggest naloxone could offer neuroprotection in cases of spinal cord injury, potentially by preserving blood flow through the modulation of vasogenic tone.
